J-M Michot
45 posts
J-M Michot
@MichotJM
Internal Medicine pract. at Gustave Roussy, in Early Drug Unit. News therapies solutions to be proposed to all pts with hard-to-treat diseases. Tweet my owns.
Paris, France Katılım Nisan 2017
147 Takip Edilen131 Takipçiler
J-M Michot retweetledi
De l’or plein les yeux pour les enfants hospitalisés de @GustaveRoussy grâce à la @PAFofficiel, marraine d’@ImagineforMargo 🤩
Mille mercis à la #PatrouilleDeFrance pour ce moment exceptionnel offert aux enfants et aux soignants de Gustave Roussy ❤️
#SeptembreEnOr
Français
J-M Michot retweetledi
Proteomics (1463 prots) identified LIF levels in the plasma as biomarker of resistance to anti-PD1 Ab. Findings validated in an independant cohort of 292 pts. Circulating LIF correlated with 3ry lymphoid structures in tumor. A study from @GustaveRoussy annalsofoncology.org/article/S0923-…
English
@y_loriot @drcmassard @GustaveRoussy thank you to @drcmassard for linking up a unique huge team in onco & hematology !and for having bring the best P1 therapies in DITEP for pts at @GustaveRoussy
English
Last day of my big big friend @drcmassard at @GustaveRoussy, One of the kindest people you can meet, he did so much for Gustave Roussy, teams and patients here !
English
J-M Michot retweetledi
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study ow.ly/KsVj50ExNMi
English
J-M Michot retweetledi
Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options
nature.com/articles/s4157…
English
Knowing better about new drugs means above all better understanding how healthy organs work. Thnks to @DrMichaelColli1 and GI team for this comprehensive report in @EXCLIJournal
Emblematic P1 + GI expert coop for
@GustaveRoussy @Hopital_Bicetre @UnivParisSaclay @LillyPad
EXCLI Journal@EXCLIJournal
#Notch inhibitors induce diarrhea, hypercrinia and secretory cell #metaplasia in the #humanColon The authors of excli.de/index.php/excl… studied #intestinal #toxicity of the Notch inhibitor #LY3039478 in cohort study. @Hopital_Bicetre @UnivParisSaclay @GustaveRoussy @LillyPad
English
J-M Michot retweetledi
#Notch inhibitors induce diarrhea, hypercrinia and secretory cell #metaplasia in the #humanColon
The authors of excli.de/index.php/excl… studied #intestinal #toxicity of the Notch inhibitor #LY3039478 in cohort study.
@Hopital_Bicetre @UnivParisSaclay @GustaveRoussy @LillyPad
English
J-M Michot retweetledi
#VACCINATION #antiCOVID19
Les points essentiels pour les personnes ayant ou ayant eu un #lymphome
Mise à jour au 11 février 2021
Lyon, France 🇫🇷 Français
J-M Michot retweetledi
2 years ago, we published a special theme issue, #LancetWomen, highlighting how gender bias has stalled women’s advancement in science, medicine, and🌎health. Today, we highlight key milestones and reinforce our commitment to #genderequality.
English
J-M Michot retweetledi
Complètement fou ! 🤩
Charlie et APIVIA franchissent la ligne d'arrivée du @VendeeGlobe à la première place au terme d'une course dingue.
Un seul mot ce soir : MERCI Charlie ! 🙏
@ApiviaMutuelle | @Apivia_courtage | @MacifAssurances
Français
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited cancerdiscovery.aacrjournals.org/content/early/…
English
J-M Michot retweetledi
SDmax captures lymphoma dissemination. SDmax and TMTV are independent prognosticators and identify high-risk DLBCL patients at baseline. A REMARC @LysaLymphoma ancillary analysis by AS Cottereau et al. see our publication at @Annals_Oncolgy doi.org/10.1016/j.anno…
English
J-M Michot retweetledi
Something is happening on the side of pancreatic cancer (300 000 death per y): PARP inh, Ras Inh, adj therapies, early detect/ctDNA. Transformation is ongoing
A top priority for Funding agencies and philanthropies (pourbertrandkamal.fr @FondationARC @DenisBrogniart @ALJ)
English
J-M Michot retweetledi
Have you ever heard of anti-ROR1? A new MOA to keep in mind for upcoming #ASH20:
VLS-101, ROR1 antibody drug conjugate (ADC) w/MMAE - Phase 1 trial in pts w/recurrent Mantle Cell and #DLBCL & Still small n but impressive results. Congrats, @michaelwangmd
English
#ASH20 : Yi Lin: CAR-T for R/R MM study CRB-401 longer FU of P1 with idecabtagene vicleucel raise the median OS = 34.2 mo in a highly prett / selected pop of pts. In the P2 the median OS is 19.4 mo and median PFS 8.8 mo. Safety update unravel frequent neutropenia (G3/4: 88.7%)
English
J-M Michot retweetledi
Looks very good
Toby Eyre@tobyeyre82
.@michaelwangmd et al #loxo-305 in R/R NHL phase I/II No DLTs or MTD reached 3 prior lines - high risk pts Post BTKi ORR in 56 MCL 52% v minimal toxicity longer fup for DoR needed WM ORR v promising 68% post BTKi Global Phase III in R/R MCL planned #lymsm #ASH20
English
#ASH20 Sham Mailankody: FIH anti-bcma ALLO-CAR-T cells in r/r multiple myeloma; 90% treated in 5 days of enrollement ! Dose cells responses / up-to 60% ORR => Most than encouraging.
English
J-M Michot retweetledi
In @NEJM ➡️ Cancer pts receiving immunosuppressive Rx may shed viable #COVID19 virus for 60 days after infection.👇Quarantine guidelines need revision. Pertinent research with huge implications on our practices. 👉🏻 bit.ly/343Bl5J @mini_kamboj & team @SocietyofMSKCC
Holladay, UT 🇺🇸 English
